📣 VC round data is live. Check it out!

Diamond Biofund Valuation Multiples

Discover Diamond Biofund's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Pembroke VCT, Moneda Renta Variable Chile, Infinity Capital Inv, Barings Corporate Invts and more.

Diamond Biofund Overview

About Diamond Biofund

Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting global and internationally competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.


Founded

2013

HQ

Taiwan

Employees

N/A

Financials (FY)

Revenue: -
Net Income: -

EV

$238M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Diamond Biofund Financials

Diamond Biofund P&L

In the most recent fiscal year, Diamond Biofund reported revenue of - and net income of -.

See analyst estimates for Diamond Biofund
202320242025202620272028
EBITDA($82M)($75M)($36M)
Net Profit($82M)($80M)($37M)

Financial data powered by Morningstar, Inc.

Diamond Biofund Stock Performance

Diamond Biofund has current market cap of $359M, and enterprise value of $238M.

Market Cap Evolution


Diamond Biofund's stock price is $0.42.

Diamond Biofund share price increased by 6.7% in the last 30 days, and decreased by 34.3% in the last year.

See more trading valuation data for Diamond Biofund
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$238M$359M0.6%6.7%-4.3%-34.3%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Diamond Biofund Valuation Multiples

Diamond Biofund Financial Valuation Multiples

As of June 3, 2026, Diamond Biofund has market cap of $359M and EV of $238M.

202320242025202620272028
EV/EBITDA(2.9x)(3.2x)(6.5x)
EV/EBIT(46.0x)(41.3x)(47.4x)
P/E(4.4x)(4.5x)(9.6x)
EV/FCF(2.9x)6.6x(28.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Diamond Biofund Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Diamond Biofund Margins & Growth Rates

See estimated margins and future growth rates for Diamond Biofund

Diamond Biofund Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth(8%)(52%)
EBIT Growth11%(13%)
Net Profit Growth(3%)(53%)
FCF Growth(143%)(124%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Diamond Biofund Competitors

Diamond Biofund competitors include Pembroke VCT, Moneda Renta Variable Chile, Infinity Capital Inv, Barings Corporate Invts, CapMan, ABC arbitrage, Longshield Investment, Millenium Hospitality, Pengana Private Equity and The RMR Group.

Most Diamond Biofund public comparables operate across Asset Management.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pembroke VCT146.3x---
Moneda Renta Variable Chile--111.1x-
Infinity Capital Inv(8.5x)-(15.9x)-
Barings Corporate Invts14.6x---
CapMan5.5x5.1x12.6x11.1x
ABC arbitrage5.3x5.0x11.8x10.7x
Longshield Investment6.4x---
Millenium Hospitality16.5x15.5x15.5x28.7x

This data is available for Pro users. Sign up to see all Diamond Biofund competitors and their valuation data.

Start Free Trial

Investments by Diamond Biofund

Diamond Biofund has invested in 5 companies to date.

Latest investment by Diamond Biofund was on November 8th 2023. Diamond Biofund invested in StemCyte in their $6M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Diamond Biofund

StemCyte
Syncell
EyeYon
Yuezige
Description
StemCyte Inc. is a Covina, California-headquartered umbilical cord blood stem cell provider founded in 1997. It supplies transplant products for blood cancers, immune disorders, and genetic conditions to centers worldwide. Storage facilities operate in California, Taiwan, and India.
Syncell is a Menlo Park-based proteomics company offering Microscoop technology for subcellular protein isolation. The microscopy-guided laser system extracts proteins from specific cellular regions for mass spectrometry analysis, identifying disease biomarkers in cancer tissues. Applied to Alzheimer's and oncology research, Syncell partners with pharma firms like Roche. Founded in 2019, it enables spatial proteomics workflows.
EyeYon Medical is a Nes Ziona-based Israeli medical device company developing treatments for corneal edema. Incubated at the Van Leer Jerusalem Hi-Tech Park, it focuses on ophthalmic devices improving fluid drainage from the cornea post-surgery or in Fuchs dystrophy cases. The core product, a minimally invasive implant, enhances patient vision recovery. EyeYon collaborates with senior ophthalmologists and cornea surgeons for clinical trials in Israel and Europe.
Yuezige is a provider of holistic maternity and postpartum care services including organic treatments and SPA therapies. The company supports parents and infants from early pregnancy through confinement periods, addressing physical, mental, and spiritual wellness.
HQ CountryUnited StatesUnited StatesIsraelChina
HQ City
Los Angeles, CA
San Francisco, CA
Jerusalem
Shanghai
Deal Date8 Nov 202315 Sep 202315 Mar 202122 Sep 2015
RoundSeries ASeedSeries CSeries A
Raised$6M$4M$25M$2M
InvestorsDiamond BiofundDarwin Venture Management; Diamond Biofund; Harbinger Ventures; Hermes-Epitek; Taya Venture CapitalBPC Investments; CR-CP Life Science Fund; Diamond Biofund; Global health sciences venture fund; Pontifax; Rimonci Capital; TriventuresDiamond Biofund
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Diamond Biofund investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Diamond Biofund

When was Diamond Biofund founded?Diamond Biofund was founded in 2013.
Where is Diamond Biofund headquartered?Diamond Biofund is headquartered in Taiwan.
Is Diamond Biofund publicly listed?Yes, Diamond Biofund is a public company listed on Taiwan Stock Exchange.
What is the stock symbol of Diamond Biofund?Diamond Biofund trades under 6901 ticker.
When did Diamond Biofund go public?Diamond Biofund went public in 2022.
Who are competitors of Diamond Biofund?Diamond Biofund main competitors include Pembroke VCT, Moneda Renta Variable Chile, Infinity Capital Inv, Barings Corporate Invts, CapMan, ABC arbitrage, Longshield Investment, Millenium Hospitality, Pengana Private Equity, The RMR Group.
What is the current market cap of Diamond Biofund?Diamond Biofund's current market cap is $359M.
Is Diamond Biofund profitable?No, Diamond Biofund is not profitable.
How many companies Diamond Biofund has acquired to date?Diamond Biofund hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Diamond Biofund has invested to date?As of June 2026, Diamond Biofund has invested in 5 companies.
What was the last Diamond Biofund investment?On 8th November 2023 Diamond Biofund invested in StemCyte, participating in a $6M Series A round.
In what companies Diamond Biofund invested in?Diamond Biofund invested in EyeYon, Ativa Medical, StemCyte, Syncell, and Yuezige.

See public comps similar to Diamond Biofund

Lists including Diamond Biofund

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial